MDACC Study No:2010-0965 ( NCT No: NCT01314599)
Title:Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Acute Leukemia or Relapsed/refractory Myelodysplastic Syndrome
Principal Investigator:Guillermo Garcia-Manero
Treatment Agent:PM01183
Study Status:Closed
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of lurbinectedin (PM01183) that can be given to patients with advanced acute
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:PM01183
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Pharma Mar USA, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Guillermo Garcia-Manero
For Clinical Trial Enrollment:713-745-3428
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults